Sodium hyaluronate is a high molecular weight, a ubiquitous molecule that occurs naturally within the cartilage and all synovial joints. In particular, weight-bearing joints, such as ankles, knees, and hips, contain viscoelastic sodium hyaluronate. This substance has lubrication and shock-absorbing properties, allowing these joints to move normally and painlessly.
In patients with osteoarthritis, the viscoelasticity of the fluid within the synovial joint is significantly impaired, causing mechanical stress on the joint, breakdown of the articular cartilage, and, subsequently, limited and painful joint movement.

Adding hyaluronic acid to the existing joint fluid of an osteoarthritic knee helps to facilitate better knee movement, reduces pain, and has many more benefits.

Hyaluronic acid (HA) injections offer several advantages over other treatment options. These intra-articular injections, with their exceptional viscoelastic properties of highly purified sodium hyaluronate, help to improve the quality of a joint’s lubrication. This increased lubrication aids in shock absorption, reducing pain and improving joint mobility.

These beneficial effects may last for several months, following the recommended treatment cycle of intra-articular injections. Additionally, hyaluronic-acid products minimize the risk of systemic side effects and may even delay the need for total knee replacement.

Viscosupplement injections a substance similar to healthy joint fluid is one of the effective non-surgical treatment. Alsavin is injected into the joints to supplement and lubricate damaged joint fluid, reduce pain and povide movement freedom.

Alsavin 1.0% / Alsavin Supra 1.6% / Alsavin One 2.0% is a product for the relief of the pain and stiffness of the knee joint and other synovial joints in patients with degenerative and traumatic changes to synovial joint. Alsavin 1.0% / Alsavin Supra 1.6% / Alsavin One 2.0% contains sodium hyaluronate, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and water for injection.

A patient will experience pain relief within a few days after treatment. The patient should not strain their knee joint for two days after receiving Alsavin and should avoid activities such as jogging, soccer, tennis, heavy lifting, or standing for long periods. Temporary pain or swelling of the knee joint may occur after receiving a hyaluronic-acid injection.

A patient can expect to experience pain relief from an Alsavin treatment for 6 – 9 months. This effect may last for several additional months following a recommended treatment cycle of intra-articular injections.

Alsavin 1.0% is five injections in a one-week interval; Alsavin Supra 1.6% is three injections in a one-week interval, and Alsavin One 2.0% is a one-shot injection. Depending on the patient’s condition and the doctor’s suggestion, these treatments may be repeated.

Alsavin’s effectiveness in reducing pain lasts from 6 – 9 months. As recommended, after 6 months, a patient should have the injections again.

Several joints may be treated simultaneously; however, to avoid intra-articular infection, it is essential to apply the strict aseptic-injection technique. Do not reuse a syringe. Any repeat usage of a syringe carries a risk of contamination and infection of the patient.

HA injections should not be administered to patients with known hypersensitivity to sodium-hyaluronate preparations. Additionally, intra-articular injections are contraindicated in cases where infections or skin diseases are present in the area of the injection site to reduce the potential for developing septic arthritis.

Following the use of Alsavin 1.0% / Alsavin Supra 1.6% / Alsavin One 2.0%, patients may experience localized symptoms in the joint being treated, such as pain, the sensation of heat, reddening, and swelling. The following adverse events have been reported for similar products: mild, or moderate arthralgia, in rare cases skin rash, aseptic joint effusions, pruritus, and muscular cramps. Further adverse events that have been observed in very rare cases are allergic reactions, anaphylactic shock, hemarthrosis phlebitis, pseudosepsis, severe acute inflammatory reaction (SAIR), nasopharyngitis, joint stiffness, tendonitis, bursitis, fever, and myalgia.

Treatment is chosen according to the grade of osteoarthritis. Drugs, such as glucocorticoids and NSAIDs, have been widely used for the treatment of osteoarthritis; however, none of these agents provides complete treatment and they have all been associated with adverse effects.

Recently, new treatment strategies are being proposed, including anti-cytokine therapy, gene therapy, delivery of growth factors, stem-cell therapy, neurotransmitter antagonists, bisphosphonates, and lubricant agents, such as lubricin.

Alsavin 1.0% / Alsavin Supra 1.6% / Alsavin One 2.0% is sterile, non-pyrogenic, clear, non-inflammatory, highly purified sodium hyaluronate of high molecular weight, dissolved in a buffered physiological saline solution. The highly purified sodium hyaluronate is obtained from bacteria by fermentation.

The molecular weight of Alsavin is 3MDa, which is one of the highest non-animal-sourced molecular weights on the market.